A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)

  • Ryan, Jessica (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date20/12/21 → 19/12/26

Keywords

  • phase 2 study
  • Randomised clinical trial
  • treatment safety
  • treatment efficacy
  • IgA Nephropathy